BCL2 and prostate carcinoma: Elevation in the level of the BCL2 protein has been shown to provide protection from apoptosis, and the BCL2 gene family is implicated in the development of CRPC and resistance to therapy since its expression increases during progression of prostate cancers [24, 25].